The Manila Times

Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development

Pricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement Offerings priced at-the-market under ...
Le Lézard

PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference

PTC Therapeutics, Inc. today provided an update on the Company's progress and its outlook for 2026. Matthew B. Klein, M.D., Chief Executive Officer of PTC, will discuss these updates at the Company's ...
Cantech Letter

OS Therapies Enters into Warrant Inducement Agreements

OS Therapies Inc. (NYSE American: OSTX) (“OS Therapies” or the “Company”), the world leader in listeria-based cancer ...
Le Lézard

Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan

Nuvation Bio Inc. , a global oncology company focused on tackling some of the toughest challenges in cancer treatment, and Eisai Co., Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), a ...
The Manila Times

Praxis Precision Medicines Enters Its Next Chapter Following a Pivotal Year of Progress

Two NDA submissions expected by mid-February 2026 for ulixacaltamide in essential tremor and relutrigine in SCN2A/8A-DEEs, ...